Search Within

Neeta Pandit-Taskar

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (51)
  2. Meeting Abstract (50)
  3. Book Section (2)
Groups
  1. GSK Faculty (103)
  2. Molecular Imaging and Therapy Service (103)
  3. Molecular Pharmacology and Chemistry Program Faculty (103)
  4. Radiology, Department of (103)
  5. Sloan Kettering Institute Faculty (103)
  6. Medical Physics (62)

More Groups

People
  1. Steven Larson (99)
  2. Jorge Carrasquillo (53)
  3. Pat Zanzonico (35)
  4. Serge Lyashchenko (35)
  5. Michael Morris (30)
  6. Howard Scher (29)

More People

Years
  1. 2025 (1)
  2. 2023 (1)
  3. 2022 (7)
  4. 2021 (3)
  5. 2020 (1)
  6. 2019 (8)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Journal of Nuclear Medicine (21)
  3. Neuro-Oncology (9)
  4. Pediatric Blood and Cancer (8)
  5. Clinical Cancer Research (7)
  6. European Journal of Nuclear Medicine and Molecular Imaging (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. Society of Nuclear Medicine (21)
  3. Springer (14)
  4. American Association for Cancer Research (10)
  5. Oxford University Press (9)
  6. Wiley Periodicals, Inc (8)

More Publishers

Results (103)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Meeting Abstract

    Modak, S.; Pandit Taskar, N.; Kushner, B.; Zanzonico, P.; Humm, J.; Donzelli, M.; Lewis, J.; Lyashchenko, S.; Chu, B.; Larson, S.; more...
    Pediatric Blood and Cancer (2022)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of intraventricular (131)I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Journal Article

    Kramer, K.; Pandit-Taskar, N.; Kushner, B. H.; Zanzonico, P.; Humm, J. L.; Tomlinson, U.; Donzelli, M.; Wolden, S. L.; Haque, S.; Dunkel, I.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • Long-term survival from a phase 1 doseescalation trial using convection-enhanced delivery (CED) of radioimmunotherapeutic (124)I-omburtamab for treatment of diffuse intrinsic pontine glioma (DIPG)
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Tasker, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Dunkel, I. J.; more...
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Biodistribution and radiation dosimetry of intraperitoneally administered (124)I-omburtamab in patients with desmoplastic small round cell tumors
    Journal Article

    Grkovski, M.; Modak, S.; Zanzonico, P. B.; Carrasquillo, J. A.; Larson, S. M.; Humm, J. L.; Pandit-Taskar, N.
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator (225)actinium-lintuzumab
    Journal Article

    Rosenblat, T. L.; McDevitt, M. R.; Carrasquillo, J. A.; Pandit-Taskar, N.; Frattini, M. G.; Maslak, P. G.; Park, J. H.; Douer, D.; Cicic, D.; Larson, S. M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Intraperitoneal pretargeted radioimmunotherapy for colorectal peritoneal carcinomatosis
    Journal Article

    Chandler, C. S.; Bell, M. M.; Chung, S. K.; Veach, D. R.; Fung, E. K.; Punzalan, B.; Burnes Vargas, D.; Patel, M.; Xu, H.; Guo, H. F.; more...
    Molecular Cancer Therapeutics (2022)

    Fulltext@MSK | Save
  • Phase 1 dose-escalation trial using convection-enhanced delivery of radiolabeled monoclonal antibody for diffuse intrinsic pontine glioma following external radiation therapy
    Meeting Abstract

    Souweidane, M. M.; Kramer, K.; Pandit-Taskar, N.; Haque, S.; Zanzonico, P.; Carrasquillo, J. A.; Lyashchenko, S. K.; Thakur, S. B.; Khakoo, Y.; Donzelli, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save